Bulletin
Investor Alert

Topics

Income

1:46 a.m. Dec. 3, 2021 - By Tomi Kilgore
Recently IPO'd Dole reports profit and revenue growth, in face of inflation and supply chain headwindsShares of Dole PLC were indicated up nearly 1% in premarket trading Friday, after the fresh fruit and vegetables company, , reported a rise in third-quarter profit and revenue, in the face of inflationary pressures and supply chain congestion and labor shortages. Pro-forma net income rose to $29.9 million, or 31 cents a share, from $18.6 million, or 20 cents a share, in the year-ago period. Revenue rose 0.3% to $2.32 billion, while cost of sales grew 0.7% to $2.18 billion. FactSet did not have consensus estimates for earnings or revenue. Fresh fruit revenue rose 0.8% to $676.8 million, as lower volume of bananas in North American and lower pricing of bananas in Europe and pineapples in North America offset higher banana pricing in North American and volume growth in pineapples. Fresh vegetables revenue increased 1.0% to $323.8 million as higher pricing in its value-added salads business offset lower volumes. For 2021, the company is expecting revenue of $9.2 billion to $9.4 billion. The stock has tumbled 16.7% over the past three months while the S&P 500 has gained 0.9%.
5:07 a.m. Nov. 16, 2021 - By Tonya Garcia
On Holding stock soars after surprise profitOn Holding AG stock soared 21% in early Tuesday trading after the newly-public athletic company reported a surprise third-quarter profit. Net income totaled CHf 13.0 million (US$14.0 million), or CHf 0.04 per share, up from CHf 8.1 million, or CHf 0.03 per share, last year. Sales totaled CHf 218.0 million (US$234.8 million), up from CHf 130.1 million last year. The FactSet consensus was for a loss of CHf 0.11 per share and sales of CHf 182.8 million. On's Co-Chief Executive Martin Hoffmann called the most recent quarter the "strongest" in the company's history in terms of sales. "Recent supply chain challenges will lead to a transitory supply shortage in the fourth quarter and the first half of 2022," he said in a statement. "But since early November, all our production factories are open, and our outlook on net sales and adjusted EBITDA exceeds our original assumptions." The company is guiding for sales of CHF 710 million for the full year, up about 67% from 2020. The FactSet consensus is for CHf 678.6 million. On is guiding for sales of CHF 960 million for 2022. On Holding stock began trading on Sept. 15. Shares have soared by nearly 50% over the past month. The S&P 500 index is up 5.1% for the last month.
2:32 a.m. Nov. 16, 2021 - By Ciara Linnane
Moderna says EU and EEA to donate more than 70 million COVID-19 vaccine does to Covax program in 2021Moderna Inc. said Tuesday the European Union and European Economic Area countries have agreed to donate more than 70 million doses of the company's COVID-19 vaccine to the Covax program in 2021, helping the World Health Organization-backed organization deliver vaccines to low-income countries. The initiative was led by France, Sweden and Norway and includes an initial donation of 15 million doses from France and 40 million from Germany. Covax is co-led by Gavi, the Vaccine Alliance (Gavi), the Coalition for Epidemic Preparedness Innovations (CEPI) and the WHO and seeks to ensure vaccine supply for all countries, regardless of income levels. Moderna shares were down 1.1% premarket but have gained 125% in the year to date, while the SPDR S&P Biotech ETF has fallen 12% and the S&p 500 has gained 25%.
6:12 a.m. Nov. 9, 2021 - By Tomi Kilgore
BioNTech stock reverses lower after earnings report, in which profit and revenue beat expectationsShares of BioNTech SE dropped 2.9% in morning trading Tuesday, reversing an earlier intraday gain of as much as 4.3%, in the wake of the Germany-based biotechnology company's better-than-expected third-quarter earnings report. The company reported before the open that it swung to net income of EUR3.21 billion ($3.72 billion), or EUR12.35 a share, from a loss of EUR210.0 million, or EUR0.88 a share, in the year-ago period, to beat the FactSet consensus for earnings per share of EUR10.54. Revenue multiplied to EUR6.09 billion ($7.05 billion) from EUR67.5 million, to beat the FactSet consensus of EUR5.10 billion, citing "rapid increases in the supply and sales of the COVID-19 vaccine worldwide." The company said it has delivered a total of more than 2 billion doses of its and Pfizer Inc.'s COVID-19 vaccine as of Nov. 2. The company said it now expects to deliver up to 2.5 billion doses of the vaccine in 2021 for revenue of about EUR16 billion to EUR17 billion, compared with guidance provided in August of about EUR15.9 billion in vaccine revenue from the delivery of about 2.2 billion doses. The company and Pfizer expect to manufacture 2.7 billion to 3.0 billion doses of the COVID-19 vaccine by the end of the year, and expect to boost manufacturing capacity to 4 billion doses in 2022. Regarding its cancer treatment business, BioNTech said it has four programs in Phase 2 development. BioNTech's stock has tumbled 47.3% over the past three months but has still run up 189.1% year to date, while the S&P 500 has gained 5.6% the past three months and rallied 24.7% this year.
1:18 a.m. Oct. 22, 2021 - By Tomi Kilgore
Autoliv stock falls after profit falls more than 50% to miss expectations as supply shortages weighed on LVPThe U.S.-listed shares of Autoliv Inc. fell 0.6% in premarket trading Friday, after the Sweden-based auto safety systems maker reported third-quarter adjusted profit that was half of last year's and missed expectations, as shortages of semiconductor supplies and other components led to a 20% drop in light vehicle production (LVP). Net income fell to $60 million, or 68 cents a share, from $99 million, or $1.12 a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share dropped 50.7%, to 73 cents from $1.48, to miss the FactSet consensus of 81 cents. Sales declined 9.3% to $1.85 billion, just below the FactSet consensus of $1.87 billion. For 2021, the company expects sales growth of "around 11%," while the current FactSet consensus of $8.41 billion implies 13% growth. "The decline in LVP, unpredictable changes in customer call-offs and higher raw material costs resulted in reduced profitability despite significant cost control measures, including headcount reductions," said Chief Executive Mikael Bratt. The stock has gained 3.4% year to date through Thursday, while the S&P 500 has climbed 21.3%.
2:21 a.m. Oct. 14, 2021 - By Tonya Garcia
Walgreens profit and sales beat expectationsWalgreens Boots Alliance Inc. shares rose 2.5% in Thursday premarket trading after the pharmacy retailer reported fiscal fourth-quarter earnings and sales that beat expectations. Net income totaled $627 million, or 72 cents per share, up from $373 million, or 43 cents per share, last year. Adjusted EPS of $1.17 beat the FactSet consensus for $1.02. Sales of $34.26 billion rose from $30.37 billion and were also ahead of the FactSet consensus for $33.03 billion. U.S. comparable pharmacy sales rose 8.1% while Boots UK comparable pharmacy sales were up 11.4%. U.S. comparable retail sales increased 8.9% while Boots UK comparable retail sales rose 15%. Walgreens provided 13.5 million COVID-19 vaccinations in the quarter, and 34.6 million for the entire fiscal year. Walgreens has a virtual investor conference taking place on Thursday. Walgreens stock has gained 18.5% for the year to date, outpacing the S&P 500 index , which is up 16.2% for the period.
3:11 a.m. Sept. 7, 2021 - By Steve Gelsi
Online betting company Sportradar eyes $500 million in IPO proceedsSwiss-based online betting service Sportrader Group AG on Tuesday said it plans to offer 19 million shares at $25 to $28 per share in its upcoming initial public offering under the symbol SRAD on the Nasdaq. Based on the midpoint of the range, the company will raise about $504 million. With about 1.1 billion Class A and Class B ordinary shares to be outstanding after the IPO, Sportradar will have a market capitalization of about $29 billion based on the midpoint of the IPO price range. The company generated $26.1 million of net income and revenue of $478 million in 2020. Sportradar is selling Class A ordinary shares in the IPO. Following the IPO, founder and CEO Carsten Koerl will be the only holder of Class B shares and will hold about 82% of the voting power. Entities affiliated with Eldridge and Radcliff Management LLC agreed to buy $159 million of Class A shares at the IPO price, as part of the deal. J.P Morgan, Morgan Stanley, Citigroup and UBS Investment Bank are joint bookrunners on the IPO, with several other banks also underwriting the offering.
2:25 a.m. Aug. 5, 2021 - By Tonya Garcia
Papa John's earnings beat expectations, dividend raisedPapa John's International Inc. reported second-quarter net loss of $79.9 million, or $2.30 per share, after net income of $15.7 million, or 48 cents per share, last year. Adjusted EPS of 93 cents beat the FactSet consensus for 74 cents. Revenue of $515.0 million was up from $460.6 million and also ahead of the FactSet consensus for $494.0 million. Comparable sales rose 5.2% in North America and were up 21.2% internationally. The FactSet consensus was for a 1% rise domestically and 18.4% growth around the world. Papa John's announced a 55.6% increase in the annual dividend to $1.40 from 90 cents. For the third quarter, the company has declared a 35-cent dividend to be paid on August 27 to shareholders of record at the close of business on August 16. Papa John's also announced an expanded partnership with Drake Food Service International that will result in 220 additional Papa John's restaurants by 2025, including more than 170 across Latin America, Spain and Portugal where Drake operates more than 280 restaurants and 50 in the U.K. In total Drake will run 560 Papa John's locations. In , Papa John's announced a new London headquarters. Papa John's stock has gained 35.7% for the year to date while the S&P 500 index is up 17.2% for the period.
1:20 a.m. July 28, 2021 - By Ciara Linnane
Dole revises IPO terms, now plans to offer 30.3 mln shares priced at $16 to $17 each Fruit and vegetable distributor Dole PLC revised the terms of its initial public offering on Wednesday, and will now offer 30.3 million shares, priced at $16 to $17 each. The company was previously planning to offer 26 million shares, priced at $20 to $23 each. The company would raise $515 million at the top of that range, at a valuation of $1.7 billion. The Dublin, Ireland-based company plans to list on the New York Stock Exchange under the ticker 'DOLE.' Goldman Sachs & Co., Deutsche Bank and Davy are the lead underwriters in a syndicate of seven banks working on the deal. Dole had pro forma revenue for fiscal 2020 of $9 billion with pro forma net attributable income of $80.1 million and adjusted pro forma net attributable income of $123.7 million. For the quarter ended March 31, 2021, pro forma revenue for Dole Plc was $2.27 billion and net income was $52.7 million. The Renaissance IPO ETF has fallen 4.6% in the year to date, while the S&P 500 has gained 17%.
1:20 a.m. July 16, 2021 - By Tomi Kilgore
Autoliv stock sinks toward 4-month low after earnings miss, citing chip shortage and rising costsShares of Autoliv Inc. sank 6.8% toward a four-month low in premarket trading Friday, after the Sweden-based maker of automotive safety systems reported second-quarter profit and sales that missed expectations and cut its full-year outlook, citing the continued impact of the COVID-19 pandemic, the negative effect of the semiconductor shortage and continued rise in raw material prices. The company swung to net income of $104 million, or $1.19 a share, from a loss of $175 million, or $2.00 a share, in the year ago period. Excluding nonrecurring items, adjusted earnings per share came to $1.20, below the FactSet consensus of $1.38. Sales jumped 93.0% to $2.02 billion, but was just shy of the FactSet consensus of $2.04 billion. The company lowered its 2021 net sales growth guidance to 20% to 22% from "around 23%." The company said prices of some key commodities has increased by more than 20% in the past three months, and expects full-year raw material costs to be a 130 basis point headwind to operating margin. "Supply shortage of semiconductors resulted in a Q2 [light vehicle production] that was 8% lower than what was expected at the beginning of the quarter, and 8% lower than th efirst quarter (according to IHS Markit, June 2021)," said Chief Executive Mikael Bratt. The stock has gained 3.1% year to date through Thursday, while the S&P 500 has advanced 16.1%.
3:32 a.m. May 19, 2021 - By Tonya Garcia
TJX earnings beat expectations though COVID-related store closures still weighTJX Cos. reported fiscal first-quarter net income of $533.9 million, or 44 cents per share, after a loss of $887.5 million, or 74 cents per share, last year. Sales of $10.09 billion were up from $4.41 billion last year. The FactSet consensus was for EPS of 31 cents and sales of $8.61 billion. All U.S. stores were operating during the quarter, but the off-price retailer still had locations shuttered in other regions for 14% of the days in the first quarter due to COVID-19. European locations were closed for 76% of the days, and Canadian stores were closed 25%. Still, it was a marked improvement from last year when stores around the world were shut for half the days. Three hundred locations around the globe are currently temporarily closed. Open-only comp store sales were up 16% in the most recent quarter. Open-only comp store sales only account for the days when stores were open during fiscal Q1 2022 and the same period in fiscal 2020. Due to the continued uncertainty of the pandemic, TJX did not provide guidance. However, the company said open-only comp store sales at the start of the second quarter have been similar to the first quarter. The TJX lineup includes TJ Maxx and HomeGoods. TJX stock slipped 0.9% in Wednesday premarket trading, but is up 4.2% for the year to date. The S&P 500 index has gained 9.9% for 2021 so far.
2:01 a.m. April 23, 2021 - By Ciara Linnane
Schlumberger shares jump 2% premarket as earnings beat estimatesSchlumberger Ltd. shares rose 2% in premarket trade Friday, after the energy giant posted better-than-expected earnings for the first quarter. The company had net income of $299 million, or 21 cents a share, in the quarter, down from $374 million, or 27 cents a share, in the year-earlier period. Revenue fell to $5.223 billion from $5.532 billion. The FactSet consensus was for EPS of 19 cents and revenue of $5.089 billion. Revenue was reduced by the divestiture of certain North America businesses in the fourth quarter of 2020, which generated $285 million in revenue in the fourth quarter of 2020 and $659 million in the first quarter of 2020. Excluding those divestitures, revenue was flat sequentially and down 23% year-on-year. "Looking ahead, we continue to be encouraged by constructive macroeconomic drivers. While the world is still grappling with COVID-19 infection rates, vaccination programs and fiscal stimulus packages are expected to support a rebound of economic activity and oil demand recovery through the year," Chief Executive Olivier Le Peuch said in a statement. Shares have gained 16% in the year to date, while the S&P 500 has gained 10%.
2:26 a.m. March 31, 2021 - By Tonya Garcia
Walgreens sales miss expectations after weak cold and flu seasonWalgreens Boots Alliance Inc. reported fiscal second-quarter net income of $1.03 billion, or $1.19 per share, up from $946.0 million, or $1.07 per share last year. Adjusted EPS of $1.40 beat the FactSet consensus for $1.10 per share. Sales of $32.78 billion were up from $31.34 billion last year but below the FactSet consensus for $36.59 billion. Walgreens total excludes sales from discontinued operations of $4.8 billion. Comparable sales in the U.S. fell 3.5% due to a weak cough, cold and flu season. Comp sales for Boots UK fell 17.9% as COVID-19 restrictions reduced foot traffic on major high streets and transportation hubs. "Overall, we have achieved a good financial quarter with results well ahead of expectations, despite significant impacts from COVID-19, and we have raised our full-year EPS guidance," said Walgreens' new Chief Executive Roz Brewer in a statement. The former Starbucks Corp. executive assumed the role on . "I am optimistic about our ability to drive sustainable, long-term value for our shareholders, while acknowledging that there is still work to be done to stabilize the base business." Walgreens raised its fiscal 2021 adjusted EPS guidance to mid-to-high single digit growth in constant currency from low single-digit growth. The pharmacy retailer also expects the $6.5 billion divestiture of to be complete before the end of the fiscal year. Walgreens says it has administered eight million COVID-19 vaccinations and conducted five million COVID-19 tests. Walgreens stock rose 2.6% in Wednesday premarket trading and have gained 15.8% over the past year. The S&P 500 index is up 53.2% for the last 12 months.
5:47 p.m. March 14, 2021 - By Janet Kersnar
As U.K. eases COVID-19 lockdown restrictions, Pandemic Year 2 provides equal helpings of anxiety and hope Camden, a North London hamlet home to both haves and have-nots, attempts to get back on its feet one year laterCamden, a North London hamlet home to both the haves and have-nots, attempts to get back on its feet one year later.
3:06 a.m. Feb. 24, 2021 - By Tonya Garcia
TJX profit and sales take a hit after COVID-19-related store closuresTJX Cos. shares fell 2.7% in Wednesday premarket trading after the off-price retailer reported fourth-quarter earnings and sales that missed expectations. Net income totaled $325.5 million, or 27 cents per share, down from $984.8 million, or 81 cents per share last year. Sales totaled $10.94 billion, down from $12.21 billion last year. The FactSet consensus was for EPS of 62 cents and sales of $11.48 billion. TJX, whose portfolio of stores includes TJ Maxx and Marshalls, says Q4 sales took a $950 million to $1.05 billion hit due to COVID-19-related store closures in Canada and Europe. Earnings per share were reduced by 18 cents to 21 cents. Stores in Canada were closed for about 32% of the fourth quarter, and European stores were closed 63%. There are currently about 690 stores closed due to the pandemic, most in Europe where the company expects stores to be closed for 67% of the first quarter. Due to the ongoing uncertainty from the coronavirus, TJX did not provide financial guidance. TJX stock has gained 13.7% over the past year while the S&P 500 index is up 20.3% for the period.
2:08 a.m. Feb. 23, 2021 - By Tomi Kilgore
Medtronic profit falls less than forecast, while revenue rises above expectationsMedtronic PLC reported Tuesday fiscal third-quarter profit that fell less than expected, while sales rose more than forecast. The medical technology and services company's stock slipped 2.0% in premarket trading, after rising 2.1% on Monday. Net income for the quarter to Jan. 29 fell to 1.27 billion, or 94 cents a share, from $1.92 billion, or $1.42 a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share declined to $1.29 from $1.44, but topped the FactSet consensus of $1.15. Sales rose 0.8% to $7.78 billion, matching the FactSet consensus. Among the company's business segments, cardiac and vascular sales fell shy of expectations, while minimally invasive therapies, restorative therapies and diabetes sales rose above expectations. The company did not provide financial guidance given uncertainties resulting from the COVID-19 pandemic. "Our Q3 results reflect that our business is well on the way to returning to growth, with sequential improvements in both revenue and earnings, despite the impact of the COVID resurgence on procedure volumes in late December and January," said Chief Executive Geoff Martha. The stock has gained 4.3% over the past three months through Monday, while the S&P 500 has advanced 8.4%.
10:32 a.m. Feb. 20, 2021 - By Quentin Fottrell
We were friendly with our neighbors for decades, until recently. One day, they introduced us to their financial adviser… ‘We dug trenches, poured concrete foundations, and worked to build our house; they hired contractors. They traded in cars frequently; we ran ours into the ground’‘We dug trenches, poured concrete foundations, and worked to build our house; they hired contractors. They traded in cars frequently; we ran ours into the ground.’
2:48 a.m. Feb. 19, 2021 - By Jaimy Lee
J&J submits application for its COVID-19 vaccine to the WHOShares of Johnson & Johnson gained 0.4% in premarket trading on Friday after the company said it had submitted an application for its experimental single-dose COVID-19 vaccine to the World Health Organization for emergency authorization. Obtaining an emergency-use listing from the WHO allows J&J's vaccine candidate to be made available through Covax, a global consortium supplying COVID-19 vaccines to lower-income countries. J&J's vaccine, which has not yet been authorized for use in the U.S., is set to be reviewed by a group of vaccine experts next week as part of the Food and Drug Administration's regulatory process. The company also submitted a regulatory application for its coronavirus vaccine in the European Union on Feb. 15. J&J's stock is up 11.3% over the past year, while the S&P 500 is up 16.3%.
3:20 a.m. Feb. 11, 2021 - By Tomi Kilgore
Kellogg stock slips after profit and sales miss, but guidance is for surprise earnings growth this yearShares of Kellogg Co. slipped 0.2% in premarket trading Thursday, after the cereal and snacks company reported fourth-quarter profit and sales that missed expectations, but pointed toward surprise growth in full-year earnings. Net income for the quarter to Jan. 2 rose to $385 million, or 59 cents a share, from $360 million, or 42 cents a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share slipped to 86 cents from 91 cents, but below the FactSet consensus of 89 cents. Sales rose 7.5% to $3.46 billion, but came up shy of the FactSet consensus of $3.51 billion. Europe showed the strongest growth with sales rising 15%, led by cereal. North America sales rose 8%, as strength in retail channel sales helped offset weakness in away-from-home channels. For 2021, the company expects adjusted EPS to rise about 1%, while the current FactSet EPS consensus of $3.96 implies a 0.8% decline. The stock has dropped 11.4% over the past three months through Wednesday, while the SPDR Consumer Staples Select Sector ETF has eased 1.4% and the S&P 500 has gained 9.4%.
2:16 a.m. Feb. 11, 2021 - By Tomi Kilgore
Molson Coors stock sinks after profit, revenue miss as Europe weakness weighsShares of Molson Coors Beverage Co. sank 3.1% in premarket trading Thursday, after the beer brewer reported a fourth-quarter adjusted profit and sales that missed expectations, weighed by weakness in Europe amid further on-premise restrictions in the U.K. amid a surge in COVID-19 cases. On a net basis, the company swung to a net loss of $1.37 billion, or $6.32 a share, from income of $163.7 million, or 75 cents a share, in the year-ago period. Excluding nonrecurring items, such as a $1.5 billion Europe goodwill impairment charge, adjusted earnings per share declined to 40 cents from $1.02, missing the FactSet consensus of 77 cents. Sales fell 7.7% to $2.29 billion, below the FactSet consensus of $2.41 billion, as North America sales slipped 0.8% while Europe sales tumbled 37.2%. For 2021, the company expects sales growth in the mid-single digit percentage range, when excluding current impacts. "While uncertainty and on-premise challenges remain, particularly in Europe, we anticipate 2021 to be a year of both top-line growth, as we begin to benefit from the early successes of our revitalization plan, and of investment, as we continue to drive toward long-term revenue and underlying EBITDA growth," said Chief Financial Officer Tracey Joubert. The stock has run up 15.6% over the past three months through Wednesday, while the S&P 500 has gained 9.4%.
1:16 a.m. Feb. 11, 2021 - By Tomi Kilgore
PepsiCo stock edges up after profit and revenue top forecasts, dividend raised by 5%Shares of PepsiCo Inc. edged up 0.1% in premarket trading Thursday, after the beverage and snack company reported fourth-quarter profit that topped expectations, revenue that rose above forecasts and raised its dividend. Net income rose to $1.85 billion, or $1.33 a share, from $1.77 billion, or $1.26 a share, in the year-ago period. Excluding nonrecurring items, core earnings per share grew to $1.47 from $1.45, above the FactSet consensus of $1.46. Revenue increased 8.8% to $22.46 billion, beating the FactSet consensus of $21.80 billion. In North America, Frito-Lay revenue rose 5.7% to $5.44 billion, just shy of the FactSet consensus of $5.48 billion; Quaker Foods revenue increased 8.3% to $836 million, above expectations of $808.4 million; and PepsiCo Beverages revenue grew 8.6% to $6.79 billion, beating forecasts of $6.60 billion. Latin America revenue fell 5.2% to $2.41 billion, but beat expectations of $2.29 billion, while Europe revenue rose 3.8% to $4.04 billion to top forecasts of $3.93 billion. "We ended the year on a strong note with our global beverage business having accelerated while our global snacks and food business remained resilient in the fourth quarter," said Chief Executive Ramon Laguarta. Separately, the company raised its annual dividend by 5%, to $4.30 a share from $4.09 a share, effective with the dividend to be paid in June. The stock has lost 4.3% over the past three months through Wednesday, while the S&P 500 has gained 9.4%.
10:22 p.m. Jan. 18, 2021 - By Steve Goldstein
Logitech International shares jump after lifting outlookShares of Logitech International jumped 8% in early Swiss trade as the computer peripheral maker upgraded its 2021 outlook. It now sees 57% to 60% sales growth at constant currencies on $1.05 billion in non-GAAP operating income, compared to its previous outlook of 35% to 40% sales growth and $700 million to $725 million of operating income. Its fiscal third-quarter operating income tripled to $448 million on sales growth of 80% in constant currencies, helped by demand for accessories for webcams and tablets, video conferencing, audio and wearables and gaming.
9:22 a.m. Dec. 10, 2020 - By Ciara Linnane
U.S. sets record one-day death toll from coronavirus as FDA committee meets to review Pfizer–BioNTech vaccine FDA head says initial assessment is ‘this is a vaccine that does meet our criteria. ... But we do want to hear from the vaccine advisory committee.’The U.S. set fresh records for single-day fatalities from the coronavirus illness COVID-19 and hospitalizations, as a U.S. regulatory advisory committee gathered to offer its verdict on the vaccine developed by Pfizer Inc. and its German partner BioNTech SE.
9:26 a.m. Dec. 9, 2020 - By Ciara Linnane
U.S. coronavirus case tally climbs to 15 million from 14 million in just five days U.S. sets fresh record for COVID-19 hospitalizations; Angela Merkel pleads with Germans to limit gatherings during holidaysThe global case tally for the coronavirus illness COVID-19 climbed above 68 million on Wednesday and the U.S. tally rose above 15 million as the virus continued to race across the nation, filling hospitals with record numbers of patients
Browse topics:

Filter results by

Industry

Manufacturing (248)

Retail (205)

Financial Services (201)

Health-care (181)

Banks (179)

Food And Beverage (148)

Location

Us (1248)

Europe (24)

Canada (17)

Asia Pacific (13)

China (10)

Eu (10)

Link to MarketWatch's Slice.